Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy Transcript
PresentationOperator Good afternoon, and welcome to the Vera Therapeutics Investor Call and Webcast. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Vera website following the conclusion of the event. I'd now like to turn the call over to Marshall Fordyce, Founder and Chief Executive Officer of Vera Therapeutics. Please go ahead, Marshall. ...